Contact
Biography
Christopher P. Fox graduated from the University of Leicester Medical School with distinction in both clinical and written examinations and was awarded the Charles Lawson Prize as the top medical student in the graduate year of 1999.
During postgraduate clinical training as a specialist registrar in Clinical Haematology, he was awarded a Clinical Research Training Fellowship from the leading UK blood cancer charity, Leukaemia and Lymphoma research (now Blood Cancer UK). He underwent intensive laboratory-based scientific training in the field of lymphoma pathobiology and viral immunology under the supervision of Professors Alan Rickinson FRS and Martin Rowe at the University of Birmingham. He was awarded a PhD in 2011 entitled "Investigating the role of Epstein-Barr virus in the pathogenesis of NK and T cell lymphoproliferations.
He was appointed Consultant Haematologist at Nottingham University Hospitals NHS Trust in 2011, specialising in lymphoid malignancies and stem cell transplantation. In 2022, he was appointed Professor of Haematology at the University of Nottingham (Centre for Cancer Sciences, Academic Unit of Translational Medical Sciences, School of Medicine). He is also an honorary research fellow at the University of Birmingham.
Research Summary
My research is clinically focused, aimed at improving survival outcomes for patients with lymphoid malignancies, particularly those with rare and aggressive blood cancers. Examples of active research… read more
Current Research
My research is clinically focused, aimed at improving survival outcomes for patients with lymphoid malignancies, particularly those with rare and aggressive blood cancers. Examples of active research themes include:
i. Clinical trials of novel therapeutics with a focus on immunotherapy in lymphoma
Extensive industry (global pharmaceutical and biotechnology companies) collaborations on early drug development including UK lead investigator and global steering committee roles for early and late phase clinical studies of bi-specific antibody therapies in B cell lymphoma.
Academic-led protocol development and national/international collaboration on early and late phase studies in aggressive lymphoma, coordinated through the NCRI aggressive lymphoma study group and Therapy Acceleration Programme (TAP) early-phase trials network in the UK. This work includes studies in progress, recently funded studies and protocols in development; as study lead, co-lead or trial-steering roles
ii. Central Nervous System Lymphoma (CNSL)
A rare and clinicopathologically unique group of rare diseases for which I have a national and international reputation for clinical research, including:
- Early and late phase clinical trial leadership, including grantholder as Chief Investigator for national and internatonal IMP studies.
- Translational science collaboration with world-leading scientific groups with a focus on biological heterogeneity and risk stratification
- Advanced imaging (magnetic resonance imaging of the brain) collaborations with Professor Dorothee Auer and Associate Professor Steffi Thust (University of Nottingham) with active studies on PCNSL imaging data from both clinical trials and routine clinical practice
- Real-world data analyses of CNSL clinical data; analysis of clinical data and hypothesis-generation through regional, national and international datasets